Delivering on our promises

ANNUAL REPORT 2018
Download our Annual Report 2018

KEY FIGURES

0

NET SALES (SEKm)

0

NUMBER OF EMPLOYEES

0

EBITDA (SEKm)

SALES SPLIT PER 
SEGMENT 2018

Steriles & Inhalation 41%
Solids & Others 44%
Development & Technology 15%

EBITDA PER 
SEGMENT 2018

Steriles & Inhalation 45%
Solids & Others 36%
Development & Technology 19%

Financial performance

FINANCIAL TARGETS AND RESULTS

results
2018

results
2017

results
2016

Annual sales should exceed SEK 8 billion by 2020

6.4

billion SEK

5.3

billion SEK

4.7

billion SEK
EBITDA margin should be higher than 16 percent

15.5

13.7

16.0

Net debt to equity should be less than 0.8

0.7

0.7

0.4

A dividend return of 30–50 per cent profit after tax

1.25

SEK/ SHARE

0

SEK/ SHARE

1.50

SEK/ SHARE
Read more

Creating value

For our customers and shareholders
Read our value proposition

SUSTAINABILITy

At Recipharm we believe that high ethical standards, accountability and good stakeholder relations create long-term benefits. This approach should be a guiding principle for all our decisions, policies and activities.
SUSTAINABILITY FOCUS AREAS

We have identified three focus areas going forward. More information about the rationale behind our priorities is included in our GRI Appendix.

Reduced greenhouse
gas emissions

Supplier assessment
and monitoring

Economic value

Read more